



Feidhmeannacht na Seirbhíse Sláinte, Seirbhís Aisíocaíochta Cúraim Phríomhúil  
Bealach amach 5, M50, An Bóthar Thuaidh, Fionnghlas  
Baile Átha Cliath 11, D11 XKF3  
Fón: (01) 864 7100 Facs: (01) 834 3589

Health Service Executive, Primary Care Reimbursement Service  
Exit 5, M50, North Road, Finglas,  
Dublin 11, D11 XKF3  
Tel: (01) 864 7100 Fax: (01) 834 3589

Pádraig O'Sullivan, T.D.  
Dáil Éireann,  
Leinster House,  
Kildare Street,  
Dublin 2.

23<sup>rd</sup> April 2025

PQ: 16464/25

**To ask the Minister for Health if the drug mounjaro will be considered for reimbursement as a treatment for obesity; and if she will make a statement on the matter. -Pádraig O'Sullivan**

Dear Deputy O'Sullivan,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 16464/25), which you submitted to the Minister for Health for response.

The HSE is committed to providing access to as many medicines as possible, in as timely a fashion as possible, from the resources available (provided) to it.

The HSE robustly assesses applications for pricing and reimbursement to make sure that it can stretch available resources as far as possible and to deliver the best value in relation to each medicine and ultimately more medicines to Irish citizens and patients.

HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds.

There are formal processes which govern applications for the pricing and reimbursement of medicines, and new uses of existing medicines, to be funded and / or reimbursed.

The HSE considers the following criteria prior to making any decision on pricing / reimbursement, in line with the Health (Pricing and Supply of Medical Goods) Act 2013:

- (1) The health needs of the public,
- (2) The cost effectiveness of meeting health needs by supplying the item concerned rather than providing other health services,
- (3) The availability and suitability of items for supply or reimbursement,

- (4) The proposed costs, benefits, and risks of the item or listed item relative to therapeutically similar items or listed items provided in other health service settings and the level of certainty in relation to the evidence of those costs, benefits and risks,
- (5) The potential or actual budget impact of the item or listed item,
- (6) The clinical need for the item or listed item,
- (7) The appropriate level of clinical supervision required in relation to the item to ensure patient safety,
- (8) The efficacy (performance in trial), effectiveness (performance in real situations) and added therapeutic benefit against existing standards of treatment (how much better it treats a condition than existing therapies) and,
- (9) The resources available to the HSE.

**In terms of the specific details of the application for pricing and reimbursement of tirzepatide (Mounjaro®):**

**Type 2 diabetes mellitus**

- The HSE received an application for pricing and reimbursement of tirzepatide (Mounjaro®) on the 24<sup>th</sup> January 2024 from Eli Lilly (the applicant) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes.
- The first step in the process is the submission of a Rapid Review dossier (a clinical and economic dossier) to the National Centre for Pharmacoeconomics (NCPE) for assessment. The HSE commissioned the Rapid Review process on the 24<sup>th</sup> January 2024.
- The NCPE Rapid Review assessment report was received by the HSE on the 6<sup>th</sup> February 2024. A full health technology assessment (HTA) was recommended to assess the clinical effectiveness and cost effectiveness of tirzepatide (Mounjaro®) compared with the current standard of care.
- The HSE commissioned a full HTA on the 1<sup>st</sup> March 2024 as per agreed processes.
- The NCPE publishes details of medicines where the HSE has commissioned a Rapid Review assessment and / or a full health technology assessment on their website. The website is updated at regular intervals and includes assessment outcomes and updates on reimbursement for each individual medicine and indication listed. Details of the assessment(s) of tirzepatide (Mounjaro®) for Type 2 diabetes mellitus are available at: [Tirzepatide \(Mounjaro®\). HTA ID: 24003 | National Centre for Pharmacoeconomics](#)
- The HSE Corporate Pharmaceutical Unit (CPU) is the interface between the HSE and the Pharmaceutical Industry in relation to medicine pricing and reimbursement applications.
- The Drugs Group is the national committee which the HSE has in place to make recommendations on the pricing and reimbursement of medicines. The membership of the HSE Drugs Group includes public interest members. The pharmacoeconomic report will be reviewed by the HSE Drugs Group along with the outputs of any commercial negotiations, and any patient group submission(s)

received. The HSE Drugs Group will consider all of the evidence and make a recommendation to the HSE Senior Leadership Team.

- The decision making authority in the HSE is the HSE Senior Leadership Team. The HSE Senior Leadership Team decides on the basis of all the demands it is faced with (across all services) whether it can fund a new medicine, or new use of an existing medicine, from the resources that have been provided to it in line with the Health (Pricing and Supply of Medical Goods) Act 2013.

### **Weight management**

- The HSE received an application for pricing and reimbursement of tirzepatide (Mounjaro®) on the 24<sup>th</sup> June 2024 from Eli Lilly (the applicant) indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of  $\geq 30 \text{ kg/m}^2$  (obesity) or  $\geq 27 \text{ kg/m}^2$  to  $< 30 \text{ kg/m}^2$  (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).
- The first step in the process is the submission of a Rapid Review dossier (a clinical and economic dossier) to the National Centre for Pharmacoeconomics (NCPE) for assessment. The HSE commissioned the Rapid Review process on the 24<sup>th</sup> June 2024.
- The NCPE Rapid Review assessment report was received by the HSE on the 30<sup>th</sup> July 2024. A full HTA was recommended to assess the clinical effectiveness and cost effectiveness of tirzepatide (Mounjaro®) compared with the current standard of care.
- The HSE commissioned a full Health Technology Assessment (HTA) on the 27<sup>th</sup> August 2024 as per agreed processes.
- The NCPE publishes details of medicines where the HSE has commissioned a Rapid Review assessment and / or a full health technology assessment on their website. The website is updated at regular intervals and includes assessment outcomes and updates on reimbursement for each individual medicine and indication listed. Details of the assessment(s) of tirzepatide (Mounjaro®) for weight management are available at: [Tirzepatide \(Mounjaro®\). HTA ID: 24024 | National Centre for Pharmacoeconomics](#)
- The HSE Corporate Pharmaceutical Unit (CPU) is the interface between the HSE and the Pharmaceutical Industry in relation to medicine pricing and reimbursement applications.
- The Drugs Group is the national committee which the HSE has in place to make recommendations on the pricing and reimbursement of medicines. The membership of the HSE Drugs Group includes public interest members. The pharmacoeconomic report will be reviewed by the HSE Drugs Group along with the outputs of commercial negotiations, and any patient group submission(s) received. The HSE Drugs Group will consider all of the evidence and make a recommendation to the HSE Senior Leadership Team.

- The decision making authority in the HSE is the HSE Senior Leadership Team. The HSE Senior Leadership Team decides on the basis of all the demands it is faced with (across all services) whether it can fund a new medicine, or new use of an existing medicine, from the resources that have been provided to it in line with the Health (Pricing and Supply of Medical Goods) Act 2013.

Both applications remain under consideration with the HSE. The HSE cannot make any comment on possible outcomes from the ongoing process.

Yours sincerely,

Suzanne Doyle  
Primary Care Reimbursement Service

**The Health Service Executive operates the General Medical Services Scheme, which includes Medical Cards and GP Visit Cards, under the Health Act 1970, as amended. It has established a dedicated contact service for members of the Oireachtas specifically for queries relating to the status of Medical Cards and GP Visit Cards applications, which the Deputy / Senator may wish to use for an earlier response. Tel: 01-8647180 / email: [Oireachtas.pcrs@hse.ie](mailto:Oireachtas.pcrs@hse.ie)**